期刊文献+

鲍曼不动杆菌连续12年的感染分布及耐药性动态变迁 被引量:69

Dynamic changes of drug resistance and infectious distribution of Acinetobacter baumannii for twelve successive years
下载PDF
导出
摘要 目的了解本院鲍曼不动杆菌的临床分布及耐药性变迁情况。方法回顾性分析1999年1月至2010年12月本院临床标本中分离的鲍曼不动杆菌的临床感染特点及其药敏结果;用API鉴定系统及VITEK2系统进行细菌鉴定;用K-B纸片扩散法进行药敏试验;用WHONET5.4软件分析鲍曼不动杆菌的耐药性。结果鲍曼不动杆菌的临床分离率及对临床常用的19种抗菌药物耐药率,总体呈上升趋势;其感染主要发生在重症监护病房(ICU)和呼吸内科;鲍曼不动杆菌的多重耐药和泛耐药也同样主要分布在这2个病区;检出菌株数最多的标本是痰;年龄越大检出率越高。结论鲍曼不动杆菌的耐药形势严峻,其分离率和耐药率呈逐年上升趋势,其多重耐药和泛耐药比例明显增加。 Objective To understand the distribution characteristics and drug resistance of Acinetobacter baumannii in clinical specimens.Methods The result of drug susceptibility and clinical distribution of Acinetobacter baumannii from Jan 1999 to Dec 2010 in our hospital were analyzed and studied retrospectively.Acinetobacter baumannii was identified by API and VITEK2 system,and its antimicrobial resistance was determined by Kirby-Bauer method.The antimicrobial resistance rates were analyzed by WHONET 5.4 software.Results The isolation rate and the resistance rate of Acinetobacter baumannii to 19 kinds of drugs appeared increasing trend during from 1999 to 2010.Acinetobacter baumannii strains were mainly distributed at ICU wards and respiratory department,the same as the multi-drug resistance and pan-drug resistance strains.The major strains was isolated from sputum,the older the age,the higher the appearing rate.Conclusion Acinetobacter baumannii has severe drug resistance,the isolation rate of Acinetobacter baumannii is increasing and the resistance rate to drugs appears increasing trend,the number of multi-drug resistant and pan-drug resistant Acinetobacter baumannii had been increased sharply.we should enhance to this kind of isolates detection,control the A.baumannii colonization and spread in hospital in order to prevent the outbreak and epidemic of nosocomial infections.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2011年第10期755-758,共4页 The Chinese Journal of Clinical Pharmacology
关键词 鲍曼不动杆菌 抗菌药物 耐药性 Acinetobacter baumannii antimicrobial agent drug resistance
  • 相关文献

参考文献6

  • 1汪复.多重耐药铜绿假单胞菌与鲍曼不动杆菌严重感染的防治策略[J].中国感染与化疗杂志,2007,7(3):230-232. 被引量:139
  • 2Karageorgopoulos DE,Falagas ME.Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J].Lancet Infect Dis,2008;8:751-762.
  • 3Pachon J,Vila J.Treatment of multiresistant Acinetobacter baumannii infections[J].Curr Invest Drugs,2009;10:150-156.
  • 4Rafailidis PI,Ioannidou EN,Falagas ME.Ampicillin/sulbactam:current status in severe bacterial infections[J].Drugs,2007 ;67:1829-1849.
  • 5Zarrilli R,Giannouli M,Tomasone F,et al.Carbapenem resistance in Acinetobacter baumannii:the molecular epidemic features of an emerging problem in health care facilities[J].J Infect Dev Ctries,2009;3:335-341.
  • 6汪复,朱德妹,胡付品,阮斐怡,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,简翠,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,薛建昌,张泓,李万华.2008年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2009,9(5):321-329. 被引量:423

二级参考文献12

  • 1王辉,郭萍,孙宏莉,杨启文,陈民钧,朱元珏,徐英春,谢秀丽.碳青霉烯类耐药的不动杆菌分子流行病学及其泛耐药的分子机制[J].中华检验医学杂志,2006,29(12):1066-1073. 被引量:237
  • 2Clinical and I.aboratory Standards Institute(CLSI). Perform ance standards for Antimicrobial susceptibility testing[S]. M100-S17, 2007.
  • 3Clinical and Laboratory Standards Institute (CLSI). Perform anee standards for Antimicrobial susceptibility testing [S]. M100-S19,2009.
  • 4Bratu S, I.andman D, Haag R, et al. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: anew threat to our antibiotic armamentarium[J]. Arch Int Meal.2005,165(12) :1430-1435.
  • 5Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA [J]. J Antimierob Chemother, 2009, 63(3):427-437.
  • 6Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem resistant Acinetobacter baumannii producing the OXA- 23 β- lactamase in Korea[J]. J Clin Microbiol, 2005, 43(5):2241 -2245.
  • 7NaasT, LevyM, HirschauerC, et al. Outbreak ofcarbapen em resistant Acinetobacter baumannii producing the carbap enemase OXA- 23 in a tertiary care hospital of Pepcete, French Polynesta[J]. J Clin Mierohiol, 2005, 43 (9) : 4826- 4829.
  • 8Waites KB, Dully LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and invitro activity of tigecycline, a new glycylcycline antimicrobial[J]. Antimicrob Agents Chemother, 2006,50(10):3479- 3484.
  • 9Souli M, Kontopidou FV, Koratzanis E, et al. lnvitro activity of tigecycline against multiple-drug resistant, including pan resistant, Gram negative and Gram-positive clinical isolates from Greek hospitals[J]. Antimicrob Agents Chemother, 2006.50(9) :3166- 3169.
  • 10Gordon NC, Warehan, DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline [J]. J Antimicrob Chemother, 2009, 63(4) :775-780.

共引文献553

同被引文献593

引证文献69

二级引证文献362

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部